Unique ID issued by UMIN | UMIN000000593 |
---|---|
Receipt number | R000000675 |
Scientific Title | Randomized controlled trial of mizoribine for progressive IgA nephropathy |
Date of disclosure of the study information | 2007/02/05 |
Last modified on | 2018/09/21 08:13:59 |
Randomized controlled trial of
mizoribine for progressive IgA
nephropathy
Randomized controlled trial of mizoribine for progressive IgA nephropathy
Randomized controlled trial of
mizoribine for progressive IgA
nephropathy
Randomized controlled trial of mizoribine for progressive IgA nephropathy
Japan |
IgA nephropathy with moderate to severe histological alterations
Medicine in general | Cardiology | Endocrinology and Metabolism |
Nephrology |
Others
NO
Investigation of efficacy and safety of mizoribine for IgA nephropathy with moderate to severe histological alterations
Safety,Efficacy
Altered amounts of proteinuria
Alteration of serum creatinine (SCr) and the slope of reciprocal SCr
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
Active
Central registration
2
Treatment
Medicine |
Methylprednisolone pulse therapy followed by oral prednisolone administration
Methylprednisolone pulse therapy followed by oral prednisolone and mizoribine administration
15 | years-old | <= |
60 | years-old | > |
Male and Female
Patients with IgA nephropathy who underwent renal biopsy and provided a written informed consent prior to study by reading and signing the form.
1) Patients who have 5 or more of glomerular score*.
2) Patients who are between 15 and 60 years of age.
3) Patients who have potential to receive methylprednisolone pulse therapy on inpatient basis, and thereafter to receive routine medical treatment as outpatients.
*(Katafuchi R et al.Clin Nephrol 49,1998)
1) Patients who have been treated with corticosteroids or mizoribine already
2) Patients who suffered infectious diseases such as pneumonia
3) Patients whose white blood cells count is under 3,000/mm3
4) Patients who are demonstrated to have another renal disease on renal biopsy
5) Patients who have diabetes mellitus
6) Patients who are have severe heart or liver disease
7) Patients who have malignant tumors
8) Patients who are currently pregnant or are supposed to be pregnant
9) Patients who are judged to be inappropriate for participation in this study by an physician
120
1st name | |
Middle name | |
Last name | Kazuhiko Tsuruya |
Graduate School of Medical Sciences, Kyushu University
Department of Integrated Therapy for Chronic Kidney Disease
Maidashi 3-1-1, Higashi-ku, Fukuoka
092-642-5843
tsuruya@intmed2.med.kyushu-u.ac.jp
1st name | |
Middle name | |
Last name | Kosuke Masutani |
West Japan Study Group for Therapy of IgA Nephropathy
Kidney Care Unit, Kyushu University Hospital
Maidashi 3-1-1, Higashi-ku, Fukuoka
092-642-5843
masutani@kcu.med.kyushu-u.ac.jp
West Japan Study Group for Therapy of IgA Nephropathy
The Kidney Foundation, Japan
Non profit foundation
NO
2007 | Year | 02 | Month | 05 | Day |
Published
https://www.ncbi.nlm.nih.gov/pubmed/26758039
Completed
2006 | Year | 10 | Month | 01 | Day |
2006 | Year | 11 | Month | 01 | Day |
2010 | Year | 10 | Month | 01 | Day |
2007 | Year | 02 | Month | 05 | Day |
2018 | Year | 09 | Month | 21 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000675
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |